COMP <GO>
ABCL vs TNGX // NET PROFIT MARGIN
AbCellera Biologics Inc. (NASDAQ) VS. Tango Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ABCL 4
— TNGX 3
■ METRIC PARITY
LAST: $11.12 (-9.37%) • MKT CAP: $3.97B
net-margins
-60.00%
LAST: $21.76 (-4.22%) • MKT CAP: $3.83B
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABCL VS. TNGX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABCL | TNGX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.50% | -28.90% | +8.40 | ABCL | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.11% | -3.68% | -0.43 | TNGX | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 160.60% | 48.30% | +112.30 | ABCL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.60 | 26.00 | -19.40 | TNGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 5/9 | -1.00 | TNGX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 46.9 | +2.10 | ABCL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.87 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 28.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.97B | $3.83B | $143.5M | ABCL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABCL REV | TNGX REV | ABCL GROSS % | TNGX GROSS % | ABCL FCF | TNGX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $75.1M | $62.4M | — | — | -$174.1M | -$139.9M |
| FY 2024 | $28.8M | $42.1M | — | — | -$187.0M | -$132.3M |
| FY 2023 | $38.0M | $36.5M | — | — | -$43.9M | -$119.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABCL // BETA —
TNGX // BETA 0.87